539 related articles for article (PubMed ID: 27030264)
1. A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity.
Royer DJ; Gurung HR; Jinkins JK; Geltz JJ; Wu JL; Halford WP; Carr DJJ
J Virol; 2016 Jun; 90(11):5514-5529. PubMed ID: 27030264
[TBL] [Abstract][Full Text] [Related]
2. Distinguishing Features of High- and Low-Dose Vaccine against Ocular HSV-1 Infection Correlates with Recognition of Specific HSV-1-Encoded Proteins.
Carr DJJ; Gmyrek GB; Filiberti A; Berube AN; Browne WP; Gudgel BM; Sjoelund VH
Immunohorizons; 2020 Oct; 4(10):608-626. PubMed ID: 33037098
[TBL] [Abstract][Full Text] [Related]
3. Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice.
Gmyrek GB; Filiberti A; Montgomery M; Chitrakar A; Royer DJ; Carr DJJ
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999018
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells.
Khan AA; Srivastava R; Chentoufi AA; Geertsema R; Thai NT; Dasgupta G; Osorio N; Kalantari M; Nesburn AB; Wechsler SL; BenMohamed L
J Virol; 2015 Jul; 89(13):6619-32. PubMed ID: 25878105
[TBL] [Abstract][Full Text] [Related]
5. Intramuscular Vaccination With the HSV-1(VC2) Live-Attenuated Vaccine Strain Confers Protection Against Viral Ocular Immunopathogenesis Associated With γδT Cell Intracorneal Infiltration.
Nabi R; Lewin AC; Collantes TM; Chouljenko VN; Kousoulas KG
Front Immunol; 2021; 12():789454. PubMed ID: 34868077
[TBL] [Abstract][Full Text] [Related]
6. Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.
Davido DJ; Tu EM; Wang H; Korom M; Gazquez Casals A; Reddy PJ; Mostafa HH; Combs B; Haenchen SD; Morrison LA
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950407
[TBL] [Abstract][Full Text] [Related]
7. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
Osorio Y; Ghiasi H
J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
9. A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus.
Ramsey NLM; Visciano M; Hunte R; Loh LN; Burn Aschner C; Jacobs WR; Herold BC
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295919
[TBL] [Abstract][Full Text] [Related]
10. Role of CD8+ T cells and lymphoid dendritic cells in protection from ocular herpes simplex virus 1 challenge in immunized mice.
Matundan H; Mott KR; Ghiasi H
J Virol; 2014 Jul; 88(14):8016-27. PubMed ID: 24807710
[TBL] [Abstract][Full Text] [Related]
11. Impact of Type I Interferon on the Safety and Immunogenicity of an Experimental Live-Attenuated Herpes Simplex Virus 1 Vaccine in Mice.
Royer DJ; Carr MM; Chucair-Elliott AJ; Halford WP; Carr DJJ
J Virol; 2017 Apr; 91(7):. PubMed ID: 28122977
[TBL] [Abstract][Full Text] [Related]
12. A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes.
Chentoufi AA; Dasgupta G; Christensen ND; Hu J; Choudhury ZS; Azeem A; Jester JV; Nesburn AB; Wechsler SL; BenMohamed L
J Immunol; 2010 Mar; 184(5):2561-71. PubMed ID: 20124097
[TBL] [Abstract][Full Text] [Related]
13. Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107
Khan AA; Srivastava R; Vahed H; Roy S; Walia SS; Kim GJ; Fouladi MA; Yamada T; Ly VT; Lam C; Lou A; Nguyen V; Boldbaatar U; Geertsema R; Fraser NW; BenMohamed L
J Virol; 2018 Aug; 92(16):. PubMed ID: 29899087
[TBL] [Abstract][Full Text] [Related]
14. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice.
Hu K; Dou J; Yu F; He X; Yuan X; Wang Y; Liu C; Gu N
Vaccine; 2011 Feb; 29(7):1455-62. PubMed ID: 21185849
[TBL] [Abstract][Full Text] [Related]
15. Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis.
Naidu SK; Nabi R; Cheemarla NR; Stanfield BA; Rider PJ; Jambunathan N; Chouljenko VN; Carter R; Del Piero F; Langohr I; Kousoulas KG
PLoS One; 2020; 15(2):e0228252. PubMed ID: 32027675
[TBL] [Abstract][Full Text] [Related]
16. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines.
Bettahi I; Nesburn AB; Yoon S; Zhang X; Mohebbi A; Sue V; Vanderberg A; Wechsler SL; BenMohamed L
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4643-53. PubMed ID: 17898288
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits.
Nesburn AB; Burke RL; Ghiasi H; Slanina SM; Wechsler SL
Virology; 1998 Dec; 252(1):200-9. PubMed ID: 9875329
[TBL] [Abstract][Full Text] [Related]
18. Vaccination of rhesus macaques with the live-attenuated HSV-1 vaccine VC2 stimulates the proliferation of mucosal T cells and germinal center responses resulting in sustained production of highly neutralizing antibodies.
Stanfield BA; Pahar B; Chouljenko VN; Veazey R; Kousoulas KG
Vaccine; 2017 Jan; 35(4):536-543. PubMed ID: 28017425
[TBL] [Abstract][Full Text] [Related]
19. Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus 1 Vaccine Strain VC2 Expressing Equine Herpesvirus 1 (EHV-1) Glycoprotein D Generates Anti-EHV-1 Immune Responses in Mice.
Liu SA; Stanfield BA; Chouljenko VN; Naidu S; Langohr I; Del Piero F; Ferracone J; Roy AA; Kousoulas KG
J Virol; 2017 Jun; 91(12):. PubMed ID: 28404844
[TBL] [Abstract][Full Text] [Related]
20. Antibodies Are Required for Complete Vaccine-Induced Protection against Herpes Simplex Virus 2.
Halford WP; Geltz J; Messer RJ; Hasenkrug KJ
PLoS One; 2015; 10(12):e0145228. PubMed ID: 26670699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
